Anheuser Busch Inbev NV ADR (BUD)vsMerck & Company Inc (MRK)
BUD
Anheuser Busch Inbev NV ADR
$68.06
-0.71%
CONSUMER DEFENSIVE · Cap: $133.23B
MRK
Merck & Company Inc
$119.37
+2.58%
HEALTHCARE · Cap: $287.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 10% more annual revenue ($65.01B vs $59.32B). MRK leads profitability with a 28.1% profit margin vs 11.5%. BUD appears more attractively valued with a PEG of 1.60. BUD earns a higher WallStSmart Score of 61/100 (C+).
BUD
Buy61
out of 100
Grade: C+
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$158.65
Current Price
$68.06
$90.59 discount
Margin of Safety
-141.2%
Fair Value
$49.50
Current Price
$119.37
$69.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 63.3% YoY
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 24.9%
Generating 9.9B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Expensive relative to growth rate
4.8% revenue growth
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BUD
The strongest argument for BUD centers on EPS Growth, Market Cap, Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
BUD carries more volatility with a beta of 0.73 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
BUD generates stronger free cash flow (9.9B), providing more financial flexibility.
Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BUD scores higher overall (61/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BEVERAGES - BREWERS Stocks
Want to dig deeper into these stocks?